Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03595059
Title A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie

Advanced Solid Tumor

lung non-small cell carcinoma

lung small cell carcinoma

Her2-receptor negative breast cancer


Docetaxel + Mirzotamab clezutoclax

Mirzotamab clezutoclax + Paclitaxel

Mirzotamab clezutoclax

Age Groups: adult | senior
Covered Countries USA | ESP | CAN

No variant requirements are available.